Please login to the form below

Not currently logged in
Email:
Password:

Gedeon Richter strengthens its biotechnology business

Gedeon Richter, and Helm, its German partner, have purchased Strathmann Biotec for EUR 22.9m to expand both companies' biotechnology research activities

Hungary-based generics manufacturer, Gedeon Richter, and Helm, its German partner, have purchased German-headquartered Strathmann Biotec for EUR 22.9m to expand both companies biotechnology research activities.

The joint venture will be 70 per cent owned by Gedeon Richter, with Helm holding the remaining 30 per cent. The deal is subjected to regulatory approval.

Strathmann Biotec has a biotechnology plant for bacterial biotechnology, as well as an R&D laboratory and pilot plant capacity. The company employs 81 staff.

Gedeon Richter says that its strategic goal is to establish a strong biopharmaceutical line to expand its worldwide product portfolio by offering products with high added value.

16th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics